AXIM Biotech Advisory Board Member Presented at CannMed 2017 Personalized Cannabinoid Medicine Conference at Harvard

New York, New York, UNITED STATES

NEW YORK, April 13, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that Dr. Ilya Reznik, a Board-certified specialist in Adult Forensic & Clinical Neuro Psychiatry and a member of the AXIM advisory board, presented at the CannMed 2017 Conference held at the Joseph B. Martin Conference at Harvard Medical School in Boston on April 9-11, 2017.

Dr. Reznik presented a poster entitled “Cannabinoid-based Medicine as a Pivotal Model for Personalized Integrative Care” which was met with considerable interest by the scientific community.

Dr. Ilya Reznik has been a clinical practitioner utilizing medical cannabis in patient treatment for over ten years with documented contributions to the field of neuropsychiatric research. Dr. Reznik joined the AXIM advisory board in December 2016 and will be actively involved with the company’s upcoming clinical program on using cannabis-based solutions to treat drug addiction and early psychosis.

The CannMed Conference is a gathering of the greatest minds in medical cannabis research; where they discussed the work they are doing to better understand the way this remarkable plant works and how their work will shape future cannabis research and development.

About AXIM®

AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.


AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).


Contact Data